- Home
- CRBG vs MDGL Comparison
CRBG vs MDGL Comparison
Compare CRBG & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRBG | MDGL |
|---|---|---|
| Founded | 1957 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0B | 12.0B |
| IPO Year | 2022 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CRBG | MDGL |
|---|---|---|
| Price | $24.60 | $525.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | $35.67 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 4.9M | 360.0K |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.93% | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,481,000,000.00 | $180,133,000.00 |
| Revenue This Year | $16.58 | $58.39 |
| Revenue Next Year | $5.57 | $47.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.19 | $265.00 |
| 52 Week High | $36.57 | $615.00 |
Technical Indicators
Market Signals| Indicator | CRBG | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 49.63 | 62.02 |
| Support Level | $24.18 | $411.87 |
| Resistance Level | $24.70 | $610.00 |
| Average True Range (ATR) | 0.98 | 26.90 |
| MACD | 0.32 | 2.62 |
| Stochastic Oscillator | 69.39 | 65.48 |
Price Performance
Historical ComparisonAbout CRBG Corebridge Financial Inc.
Corebridge Financial Inc provides retirement solutions and insurance products in the United States. It offers a broad set of products and services through five segments Individual Retirement, Group Retirement, Life Insurance, Institutional Markets businesses, Corporate and Other. The majority of its revenue derives from the Individual Retirement segment.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.